Patient and clinical characteristics
| Characteristic . | No. . |
|---|---|
| Median age, y (range) | 50 (25-66) |
| Sex, M/F | 56/25 |
| Sibling donor/unrelated donor | 71/10 |
| Protocol | |
| Fludarabine/melphalan/Campath-1H | 37 |
| BCNU/etoposide/ara-C/melphalan/Campath-1H | 21 |
| Busulphan/fludarabine/T-cell depletion | 8 |
| Fludarabine/cyclophosphamide | 9 |
| Fludarabine/cyclophosphamide/Campath-1H | 4 |
| Fludarabine/melphalan | 2 |
| Disease | |
| AML | 10 |
| CML | 12 |
| CLL | 9 |
| Myeloma | 11 |
| NHL (n = 29) | |
| Follicular | 16 |
| High grade | 6 |
| Mantle cell | 4 |
| Unspecified | 3 |
| Hodgkin disease | 4 |
| Myelodysplastic syndrome | 2 |
| Other* | 4 |
| Remission status/stage of disease at transplantation | |
| CR1 (including 4 CML-CP1) | 15 |
| CR2 | 2 |
| CR3 or later remission | 5 |
| PR (including 2 CML-CP2) | 28 |
| Sensitive relapse | 14 |
| Untested relapse | 6 |
| Primary refractory disease | 3 |
| Resistant relapse | 8 |
| Disease status at transplantation (%) | |
| Favorable | 17 (21) |
| Intermediate | 45 (56) |
| Unfavorable | 19 (23) |
| Characteristic . | No. . |
|---|---|
| Median age, y (range) | 50 (25-66) |
| Sex, M/F | 56/25 |
| Sibling donor/unrelated donor | 71/10 |
| Protocol | |
| Fludarabine/melphalan/Campath-1H | 37 |
| BCNU/etoposide/ara-C/melphalan/Campath-1H | 21 |
| Busulphan/fludarabine/T-cell depletion | 8 |
| Fludarabine/cyclophosphamide | 9 |
| Fludarabine/cyclophosphamide/Campath-1H | 4 |
| Fludarabine/melphalan | 2 |
| Disease | |
| AML | 10 |
| CML | 12 |
| CLL | 9 |
| Myeloma | 11 |
| NHL (n = 29) | |
| Follicular | 16 |
| High grade | 6 |
| Mantle cell | 4 |
| Unspecified | 3 |
| Hodgkin disease | 4 |
| Myelodysplastic syndrome | 2 |
| Other* | 4 |
| Remission status/stage of disease at transplantation | |
| CR1 (including 4 CML-CP1) | 15 |
| CR2 | 2 |
| CR3 or later remission | 5 |
| PR (including 2 CML-CP2) | 28 |
| Sensitive relapse | 14 |
| Untested relapse | 6 |
| Primary refractory disease | 3 |
| Resistant relapse | 8 |
| Disease status at transplantation (%) | |
| Favorable | 17 (21) |
| Intermediate | 45 (56) |
| Unfavorable | 19 (23) |
BCNU indicates 1,3-bis-(2-chloroethyl)-1-nitrosourea; bleomycin and carmustine.
Other diseases treated were renal carcinoma (1), hypereosinophilic syndrome, T-prolymphocytic leukemia, and immunocytoma.